Cargando…

A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China

Objectives: One dose of Sabin-strains inactivated polio vaccine (IPV) was introduced into the Chinese immunization program on 1 May 2016. This study aimed to evaluate the safety of Sabin-strains IPV and provide a comparison with conventional Salk-strains IPV. Methods: Adverse events following immuni...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Huakun, Pan, Xuejiao, Liang, Hui, Chen, Yaping, Wang, Ying, Chen, Fuxing, Shen, Linzhi, Hu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874468/
https://www.ncbi.nlm.nih.gov/pubmed/35214777
http://dx.doi.org/10.3390/vaccines10020319
_version_ 1784657695391875072
author Lv, Huakun
Pan, Xuejiao
Liang, Hui
Chen, Yaping
Wang, Ying
Chen, Fuxing
Shen, Linzhi
Hu, Yu
author_facet Lv, Huakun
Pan, Xuejiao
Liang, Hui
Chen, Yaping
Wang, Ying
Chen, Fuxing
Shen, Linzhi
Hu, Yu
author_sort Lv, Huakun
collection PubMed
description Objectives: One dose of Sabin-strains inactivated polio vaccine (IPV) was introduced into the Chinese immunization program on 1 May 2016. This study aimed to evaluate the safety of Sabin-strains IPV and provide a comparison with conventional Salk-strains IPV. Methods: Adverse events following immunization (AEFI) records associated with Sabin-strains IPV and Salk-strains IPV were extracted from the national AEFI surveillance system (NAEFISS) from 1 May 2016 to 31 December 2020. The vaccination information on Sabin-strains IPV and Salk-strains IPV during the same period was obtained from the Zhejiang provincial immunization information system. Reporting rates of AEFI were calculated by age, city, severity of AEFI, categories of AEFI, and reaction categories and were compared between Sabin-strains IPV and Salk-strains IPV. Results: In total, 3,861,758 doses of Sabin-strains IPV and 1,018,604 doses of Salk-strains IPV were administered during the study period. The overall AEFI reporting rate for Sabin-strains IPV (3.96/10,000 doses) was significantly lower than that for Salk-strains IPV (5.03/10,000 doses) due to the reporting rate of the minor vaccine product-related reaction following Sabin-strains IPV was significantly lower than that for Salk-strains IPV (2.76/10,000 doses vs. 3.83/10,000 doses). The most frequently reported symptoms/signs were fever, induration/swelling, and rash/urticaria. The most frequently reported serious AEFI with a causal relationship was febrile convulsion, with the reporting rates of 0.10/10,000 doses for Sabin-strains IPV and 0.08/10,000 doses for Salk-strains IPV. No significant difference was found in the reporting rates of the other serious AEFI between the two types of IPV. Conclusion: Most of the AEFI following Sabin-strains IPV and Salk-strains IPV were mild and common adverse reactions. The reporting rate of serious AEFI was not significantly different between Sabin-strains IPV and Salk-strains IPV. Sabin-strains IPV had a favorable safety profile and could be widely used.
format Online
Article
Text
id pubmed-8874468
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88744682022-02-26 A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China Lv, Huakun Pan, Xuejiao Liang, Hui Chen, Yaping Wang, Ying Chen, Fuxing Shen, Linzhi Hu, Yu Vaccines (Basel) Article Objectives: One dose of Sabin-strains inactivated polio vaccine (IPV) was introduced into the Chinese immunization program on 1 May 2016. This study aimed to evaluate the safety of Sabin-strains IPV and provide a comparison with conventional Salk-strains IPV. Methods: Adverse events following immunization (AEFI) records associated with Sabin-strains IPV and Salk-strains IPV were extracted from the national AEFI surveillance system (NAEFISS) from 1 May 2016 to 31 December 2020. The vaccination information on Sabin-strains IPV and Salk-strains IPV during the same period was obtained from the Zhejiang provincial immunization information system. Reporting rates of AEFI were calculated by age, city, severity of AEFI, categories of AEFI, and reaction categories and were compared between Sabin-strains IPV and Salk-strains IPV. Results: In total, 3,861,758 doses of Sabin-strains IPV and 1,018,604 doses of Salk-strains IPV were administered during the study period. The overall AEFI reporting rate for Sabin-strains IPV (3.96/10,000 doses) was significantly lower than that for Salk-strains IPV (5.03/10,000 doses) due to the reporting rate of the minor vaccine product-related reaction following Sabin-strains IPV was significantly lower than that for Salk-strains IPV (2.76/10,000 doses vs. 3.83/10,000 doses). The most frequently reported symptoms/signs were fever, induration/swelling, and rash/urticaria. The most frequently reported serious AEFI with a causal relationship was febrile convulsion, with the reporting rates of 0.10/10,000 doses for Sabin-strains IPV and 0.08/10,000 doses for Salk-strains IPV. No significant difference was found in the reporting rates of the other serious AEFI between the two types of IPV. Conclusion: Most of the AEFI following Sabin-strains IPV and Salk-strains IPV were mild and common adverse reactions. The reporting rate of serious AEFI was not significantly different between Sabin-strains IPV and Salk-strains IPV. Sabin-strains IPV had a favorable safety profile and could be widely used. MDPI 2022-02-17 /pmc/articles/PMC8874468/ /pubmed/35214777 http://dx.doi.org/10.3390/vaccines10020319 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lv, Huakun
Pan, Xuejiao
Liang, Hui
Chen, Yaping
Wang, Ying
Chen, Fuxing
Shen, Linzhi
Hu, Yu
A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China
title A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China
title_full A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China
title_fullStr A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China
title_full_unstemmed A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China
title_short A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China
title_sort comparison with adverse events following immunization associated with sabin-strains and salk-strains inactivated polio vaccines in zhejiang province, china
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874468/
https://www.ncbi.nlm.nih.gov/pubmed/35214777
http://dx.doi.org/10.3390/vaccines10020319
work_keys_str_mv AT lvhuakun acomparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT panxuejiao acomparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT lianghui acomparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT chenyaping acomparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT wangying acomparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT chenfuxing acomparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT shenlinzhi acomparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT huyu acomparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT lvhuakun comparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT panxuejiao comparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT lianghui comparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT chenyaping comparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT wangying comparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT chenfuxing comparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT shenlinzhi comparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina
AT huyu comparisonwithadverseeventsfollowingimmunizationassociatedwithsabinstrainsandsalkstrainsinactivatedpoliovaccinesinzhejiangprovincechina